Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 7/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 7/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187234 | 0.98 | TBXAS1 (0.48) | CYP2C19TBXAS1CYP4F2CYP4A11MME | |
| SCHEMBL187310 | 0.96 | TBXAS1 (0.42) | CYP2C19TBXAS1CYP4F2CYP4A11MME | |
| SCHEMBL20402753 | 0.93 | KMT2A (0.46) | CYP2C19TBXAS1CYP4F2CYP4A11MAPT | |
| SCHEMBL187206 | 0.91 | TBXAS1 (0.37) | CYP2C19TBXAS1CYP4F2CYP4A11MAPT | |
| SCHEMBL16375047 | 0.91 | TBXAS1 (0.40) | CYP2C19TBXAS1CYP4F2CYP4A11MME | |
| SCHEMBL16375054 | 0.89 | TBXAS1 (0.43) | CYP2C19TBXAS1CYP4F2CYP4A11CETP | |
| SCHEMBL3280065 | 0.89 | TBXAS1 (0.40) | CYP2C19TBXAS1CYP4F2CYP4A11MAPT | |
| SCHEMBL9181319 | 0.89 | CYP2C19 (0.56) | CYP2C19TBXAS1CYP4F2CYP4A11MME | |
| SCHEMBL250369 | 0.88 | CYP2C19 (0.52) | CYP2C19TBXAS1CYP4F2CYP4A11KMT2A | |
| SCHEMBL16375053 | 0.87 | TBXAS1 (0.38) | CYP2C19TBXAS1CYP4F2CYP4A11CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701931-B1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2018-10-10 | — | — | EP | claimed |
| US-8642653-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-02-04 | — | — | US | claimed |
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | US | claimed |
| US-8084498-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2011-12-27 | — | — | US | claimed |
| US-7705177-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPUETICS, INC. (US) | 2010-04-27 | — | — | US | claimed |
| US-10709678-B2 | Methods of reducing risk of cardiovascular disease | NEUROBO PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2019-03-21 | — | — | US | disclosed |
| EP-1701931-B1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-10028926-B2 | Methods of reducing risk of cardiovascular disease | GEMPHIRE THERAPEUTICS INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | ESPERION THERAPEUTIC, INC. | 2006-10-12 | — | — | US | disclosed |
| US-7119221-B2 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1701931-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005068412-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, CETP | CYP2C19 431/4885TBXAS1 645/4885CYP4F2 999/4885 |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP2C19 1033/4885TBXAS1 456/4885CYP4F2 2014/4885 |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | PNLIP, APOL1, NR1H3 | CYP2C19 1278/4885TBXAS1 418/4885CYP4F2 2326/4885 |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | CYP2C19 485/4885TBXAS1 673/4885CYP4F2 1045/4885 |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP2C19 1033/4885TBXAS1 456/4885CYP4F2 2014/4885 |
| US-10028926-B2 | Methods of reducing risk of cardiovascular disease | HMGCR, LDLR, PCSK9 | CYP2C19 549/4885TBXAS1 1703/4885CYP4F2 888/4885 |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PNLIP, CYP27A1, GPR119 | CYP2C19 1035/4885TBXAS1 301/4885CYP4F2 1797/4885 |
| US-10709678-B2 | Methods of reducing risk of cardiovascular disease | HMGCR, PCSK9, LDLR | CYP2C19 537/4885TBXAS1 1649/4885CYP4F2 903/4885 |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP2C19 1033/4885TBXAS1 456/4885CYP4F2 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.